Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Glenmark Life Sciences Limited
GLSGlenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Nirma Limited. Address: OIA House, Mumbai, India, 400099
Analytics
Objectif de Cours de WallStreet
91 226.98 INRRatio C/B
31.8449Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés GLS
Analyse des dividendes GLS
Croissance des dividendes sur 5 ans
–Croissance continue
1 annéeRatio de distribution Moyenne sur 5 ans
59 %Historique des dividendes GLS
Valorisation des titres GLS
financières GLS
Résultats | 2019 | Dynamique |